Sruthi S. Balakrishnan | Oct 1, 2021 | 10+ min read
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.
Scientists uncover the promise of mesenchymal stem cells (MSCs), also known as medicinal signaling cells, to modulate the immune system and regenerate tissue.
Federal agents searched the offices of the personal microbiome testing company in San Francisco on April 26 following allegations of improperly billing health insurers.
Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.